2004
DOI: 10.1016/j.ymthe.2004.08.009
|View full text |Cite
|
Sign up to set email alerts
|

Dual Therapeutic Utility of Proteasome Modulating Agents for Pharmaco-gene Therapy of the Cystic Fibrosis Airway

Abstract: Pharmacologic- and gene-based therapies have historically been developed as two independent therapeutic platforms for cystic fibrosis (CF) lung disease. Inhibition of the dysregulated epithelial Na channel (ENaC) is one pharmacologic approach to enhance airway clearance in CF. We investigated pharmacologic approaches to enhance CFTR gene delivery with recombinant adeno-associated virus (rAAV) and identified compounds that significantly improved viral transduction while simultaneously inhibiting ENaC activity t… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

1
47
0

Year Published

2005
2005
2022
2022

Publication Types

Select...
7
1
1

Relationship

2
7

Authors

Journals

citations
Cited by 46 publications
(51 citation statements)
references
References 41 publications
1
47
0
Order By: Relevance
“…Indeed, our (and other groups) identification of HspA4, HspBP1, and other chaperones as proteins when overexpressed correct F508del-CFTR cell surface expression and function led us to test the ability of Velcade (a proteasome inhibitor that activates the cellular stress response, including stimulation of chaperones) to rescue F508del-CFTR. Our work here shows that Velcade can indeed correct F508del-CFTR function, in accordance with a recent report by Zeitlin and colleagues (43) and with a report that demonstrates rescue of mutant CFTR with the proteasome inhibitor LLnL (44). Since Velcade is already used clinically for the treatment of multiple myeloma, it may be possible to test its efficacy for treating CF.…”
Section: Discussionsupporting
confidence: 92%
“…Indeed, our (and other groups) identification of HspA4, HspBP1, and other chaperones as proteins when overexpressed correct F508del-CFTR cell surface expression and function led us to test the ability of Velcade (a proteasome inhibitor that activates the cellular stress response, including stimulation of chaperones) to rescue F508del-CFTR. Our work here shows that Velcade can indeed correct F508del-CFTR function, in accordance with a recent report by Zeitlin and colleagues (43) and with a report that demonstrates rescue of mutant CFTR with the proteasome inhibitor LLnL (44). Since Velcade is already used clinically for the treatment of multiple myeloma, it may be possible to test its efficacy for treating CF.…”
Section: Discussionsupporting
confidence: 92%
“…Four to six weeks after ALI was established, transepithelial short circuit currents (I sc ) were measured using an epithelial voltage clamp (Model EC-825) and a self-contained Ussing chamber system (both purchased from Warner Instruments, Inc., Hamden, CT) as previously described (35,36). Throughout the experiment the chamber was kept at 37ЊC, and the chamber solution was aerated.…”
Section: Short Circuit Current Measurementsmentioning
confidence: 99%
“…A number of strategies have been explored to circumvent this limitation. Some studies have used short endogenous AAV sequences as a promoter (with or without proteosomal inhibitors to increase expression) with variable results in differentiated airway epithelia (15,18,19). Other studies have produced AAV vectors with a CFTR cDNA that deletes the N terminus (15), and other deletions have been proposed for AAV vectors (16,18).…”
mentioning
confidence: 99%